155 related articles for article (PubMed ID: 26578208)
1. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models.
Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR
Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208
[TBL] [Abstract][Full Text] [Related]
2. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
[TBL] [Abstract][Full Text] [Related]
4. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.
Puri A; Kramer-Marek G; Campbell-Massa R; Yavlovich A; Tele SC; Lee SB; Clogston JD; Patri AK; Blumenthal R; Capala J
J Liposome Res; 2008; 18(4):293-307. PubMed ID: 18937120
[TBL] [Abstract][Full Text] [Related]
5. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR
PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460
[TBL] [Abstract][Full Text] [Related]
6. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
7. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).
Beuttler J; Rothdiener M; Müller D; Frejd FY; Kontermann RE
Bioconjug Chem; 2009 Jun; 20(6):1201-8. PubMed ID: 19435362
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
[TBL] [Abstract][Full Text] [Related]
9. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
[TBL] [Abstract][Full Text] [Related]
10. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
11. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice.
Alavizadeh SH; Gheybi F; Nikpoor AR; Badiee A; Golmohammadzadeh S; Jaafari MR
Mol Pharm; 2017 Mar; 14(3):712-721. PubMed ID: 28135098
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies.
Marzban E; Alavizadeh SH; Ghiadi M; Khoshangosht M; Khashayarmanesh Z; Abbasi A; Jaafari MR
Colloids Surf B Biointerfaces; 2015 Dec; 136():885-91. PubMed ID: 26547316
[TBL] [Abstract][Full Text] [Related]
14. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
15. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.
Shishido T; Mieda H; Hwang SY; Nishimura Y; Tanaka T; Ogino C; Fukuda H; Kondo A
Bioorg Med Chem Lett; 2010 Oct; 20(19):5726-31. PubMed ID: 20801029
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
[TBL] [Abstract][Full Text] [Related]
17. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
[TBL] [Abstract][Full Text] [Related]
19. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
